The University of Chicago Header Logo

Connection

Nita Lee to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Nita Lee has written about Cost-Benefit Analysis.
Nita Lee
Connection Strength
0.571
Cost-Benefit Analysis
  1. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
    View in: PubMed
    Score: 0.571
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.